Boston Scientific (BSX) Reports In-Line Prelim. Q4 Sales

Three Months Ended

Less: Impact of Foreign Currency Fluctuations

Operational Basis

2018

2017

Endoscopy

$

0.46

$

0.44

5.1%

6.7%

Urology and Pelvic Health

0.34

0.31

12.3%

MedSurg*

0.80

0.75

7.5%

(1.5)%

9.0%

Cardiac Rhythm Management

0.49

0.49

0.2%

(1.6)%

1.8%

Electrophysiology

0.08

0.08

6.4%

(1.7)%

8.1%

Neuromodulation

0.22

0.19

18.1%

(1.0)%

19.1%

Rhythm and Neuro*

0.79

0.75

5.3%

(1.4)%

6.7%

Interventional Cardiology

0.67

0.64

5.1%

(2.5)%

7.6%

Peripheral Interventions

0.30

0.28

9.3%

(2.1)%

11.4%

Cardiovascular

0.97

0.91

6.4%

(2.3)%

8.7%

Net Sales

$

2.56

$

2.41

8.2%

Three Months Ended

Change

December 31,

Reported Basis

Less: Impact of Foreign Currency Fluctuations

Operational Basis

2018

2017

(in billions / unaudited)

U.S.

$

1.46

$

1.36

7.0 %

0.0 %

7.0 %

EMEA (Europe, Middle East and Africa)**

0.56

0.53

5.1 %

(4.1) %

9.2 %

APAC (Asia-Pacific)**

0.45

0.42

5.2 %

(1.9) %

7.1 %

Latin America and Canada

0.10

0.09

7.2 %

(15.0) %

22.2 %

Net Sales

$

2.56

$

2.41

6.3 %

(1.9) %

8.2 %

Twelve Months Ended

Change

(in billions / unaudited)

December 31,

Reported Basis

Less: Impact of Foreign Currency Fluctuations

Operational Basis

2018

2017

Endoscopy

$

1.76

$

1.62

8.9 %

0.5 %

8.4 %

Urology and Pelvic Health

1.25

1.12

10.9 %

0.3 %

10.6 %

MedSurg*

3.01

2.74

9.7 %

0.4 %

9.3 %

Cardiac Rhythm Management

1.95

1.90

3.0 %

0.9 %

2.1 %

Electrophysiology

0.31

0.28

12.1 %

1.2 %

10.9 %

Neuromodulation

0.78

0.64

22.7 %

0.2 %

22.5 %

Rhythm and Neuro*

3.04

2.81

8.3 %

0.7 %

7.6 %

Interventional Cardiology

2.59

2.42

7.1 %

0.5 %

6.6 %

Peripheral Interventions

1.19

1.08

9.8 %

0.6 %

9.2 %

Cardiovascular

3.78

3.50

7.9 %

0.5 %

7.4 %

Net Sales

$

9.82

$

9.05

8.6 %

0.6 %

8.0 %

Change

December 31,

Reported Basis

Less: Impact of Foreign Currency Fluctuations

Operational Basis

2018

2017

(in billions / unaudited)

U.S.

$

5.54

$

5.16

7.3 %

0.0 %

7.3 %

EMEA**

2.18

1.94

12.2 %

3.2 %

9.0 %

APAC**

1.73

1.59

8.8 %

1.3 %

7.5 %

Latin America and Canada

0.38

0.36

6.8 %

(9.0) %

15.8 %

Net Sales

$

9.82

$

9.05

8.6 %

0.6 %

8.0 %

*Prior period segment amounts revised in accordance with ASC 280, Segment Reporting, to reflect the reclassification of Neuromodulation from the MedSurg segment to the Rhythm and Neuro segment, effective January 1, 2018.

**Regional totals reflect the reclassification of Middle East and Africa from the former AMEA region to Europe, effective January 1, 2018.

Amounts may not add due to rounding. Growth rates are based on preliminary, non-rounded amounts and may not recalculate precisely.

Operational and organic sales growth rates are not prepared in accordance with U.S. GAAP.

1. Operational revenue growth excludes the impact of foreign currency fluctuations.

2. Organic revenue growth excludes the impact of foreign currency fluctuations and sales from the recent acquisitions of Symetis SA, NxThera, Inc., Claret Medical, Inc. and Augmenix, Inc. with no prior year comparable sales.